GlassScriptPhysician profile
Adam Wesley Bruckner
NPI 1316109564
$7,729.52
in general payments reported to CMS, 2019-2025
55 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $845 · 2021: $1,178 · 2022: $1,173 · 2023: $1,319 · 2024: $1,388 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,844.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,157.30 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $1,015.12 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $983.12 | 2019-2025 | Mounjaro, Jardiance, Kisunla |
| Novo Nordisk INC | $636.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $507.65 | 2019-2025 | Jardiance |
| Amgen INC. | $342.50 | 2019-2024 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $296.96 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $282.18 | 2019-2025 | |
| Pfizer INC. | $210.86 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $152.38 | 2020-2022 | |
| Exact Sciences Corporation | $145.31 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.74 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $128.82 | 2022-2025 | Veozah, Myrbetriq |
| Idorsia Pharmaceuticals US INC | $125.66 | 2022-2024 | Quviviq |
| Allergan, INC. | $124.03 | 2019-2020 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Bruckner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.